Equities analysts expect Teleflex Incorporated (NYSE:TFX) to report $601.67 million in sales for the current fiscal quarter, according to Zacks. Five analysts have issued estimates for Teleflex’s earnings, with estimates ranging from $598.50 million to $605.30 million. Teleflex posted sales of $513.93 million during the same quarter last year, which suggests a positive year over year growth rate of 17.1%. The firm is scheduled to report its next quarterly earnings report on Thursday, February 22nd.

According to Zacks, analysts expect that Teleflex will report full-year sales of $601.67 million for the current fiscal year, with estimates ranging from $2.15 billion to $2.16 billion. For the next financial year, analysts expect that the business will post sales of $2.43 billion per share, with estimates ranging from $2.41 billion to $2.46 billion. Zacks’ sales calculations are an average based on a survey of sell-side analysts that cover Teleflex.

Teleflex (NYSE:TFX) last released its earnings results on Thursday, November 2nd. The medical technology company reported $2.12 earnings per share for the quarter, beating analysts’ consensus estimates of $2.01 by $0.11. Teleflex had a return on equity of 16.27% and a net margin of 12.41%. The company had revenue of $534.70 million during the quarter, compared to analyst estimates of $522.94 million. During the same quarter in the previous year, the company posted $1.80 EPS. Teleflex’s revenue for the quarter was up 17.3% on a year-over-year basis.

A number of research firms have recently weighed in on TFX. Morgan Stanley boosted their target price on Teleflex from $274.00 to $290.00 and gave the company an “equal weight” rating in a research note on Friday, November 3rd. Leerink Swann raised Teleflex from a “market perform” rating to an “outperform” rating and upped their price target for the company from $227.00 to $266.00 in a research report on Thursday, September 7th. Deutsche Bank lowered Teleflex from a “buy” rating to a “hold” rating and set a $251.00 price target for the company. in a research report on Tuesday, November 14th. Zacks Investment Research lowered Teleflex from a “buy” rating to a “hold” rating in a research report on Thursday, August 31st. Finally, Needham & Company LLC upped their price target on Teleflex from $237.00 to $285.00 and gave the company a “buy” rating in a research report on Friday, November 3rd. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and six have given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $274.44.

Shares of Teleflex (NYSE TFX) opened at $249.35 on Friday. Teleflex has a 52 week low of $154.77 and a 52 week high of $271.23. The company has a quick ratio of 3.70, a current ratio of 4.72 and a debt-to-equity ratio of 0.88. The firm has a market capitalization of $11,256.01, a PE ratio of 30.89, a PEG ratio of 2.14 and a beta of 1.09.

The company also recently announced a quarterly dividend, which will be paid on Friday, December 15th. Shareholders of record on Wednesday, November 15th will be issued a dividend of $0.34 per share. The ex-dividend date is Tuesday, November 14th. This represents a $1.36 dividend on an annualized basis and a dividend yield of 0.55%. Teleflex’s dividend payout ratio (DPR) is 24.82%.

In other Teleflex news, Director Stephen K. M.D. Klasko sold 200 shares of the company’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $265.32, for a total transaction of $53,064.00. Following the transaction, the director now owns 8,080 shares in the company, valued at approximately $2,143,785.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Benson Smith sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $258.10, for a total value of $516,200.00. Following the transaction, the chief executive officer now owns 76,634 shares in the company, valued at approximately $19,779,235.40. The disclosure for this sale can be found here. Insiders have sold a total of 2,600 shares of company stock worth $665,076 in the last quarter. Company insiders own 2.39% of the company’s stock.

Several institutional investors have recently bought and sold shares of TFX. Janus Henderson Group PLC grew its stake in shares of Teleflex by 50,429.2% in the 2nd quarter. Janus Henderson Group PLC now owns 1,816,020 shares of the medical technology company’s stock worth $377,296,000 after buying an additional 1,812,426 shares during the last quarter. Koch Industries Inc. grew its stake in shares of Teleflex by 47,174.3% in the 2nd quarter. Koch Industries Inc. now owns 959,669 shares of the medical technology company’s stock worth $955,000 after buying an additional 957,639 shares during the last quarter. American Century Companies Inc. grew its stake in shares of Teleflex by 41.6% in the 3rd quarter. American Century Companies Inc. now owns 1,187,909 shares of the medical technology company’s stock worth $287,438,000 after buying an additional 348,829 shares during the last quarter. Marshall Wace North America L.P. grew its stake in shares of Teleflex by 137.4% in the 2nd quarter. Marshall Wace North America L.P. now owns 518,462 shares of the medical technology company’s stock worth $107,840,000 after buying an additional 300,069 shares during the last quarter. Finally, Principal Financial Group Inc. grew its stake in shares of Teleflex by 93.5% in the 2nd quarter. Principal Financial Group Inc. now owns 610,398 shares of the medical technology company’s stock worth $126,816,000 after buying an additional 294,935 shares during the last quarter. Institutional investors own 89.31% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This article was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of international copyright laws. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/12/15/601-67-million-in-sales-expected-for-teleflex-incorporated-tfx-this-quarter.html.

About Teleflex

Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).

Get a free copy of the Zacks research report on Teleflex (TFX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Teleflex (NYSE:TFX)

Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.